|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Saturday, November 04, 2006
NEW DRUG IN PIPELINE: MBP8298: ...BioMS Medical Press Release
Mr. Kevin Giese, President and CEO, will present at the MS Society of Canada, Alberta Division's Annual General Meeting in Calgary, Alberta. WHEN: Saturday, November 4th at 1:10 pm (Mountain Time) WHERE: Greenwood Inn, Calgary, Alberta About The MS Society of Canada - Alberta Division Founded in 1980, the Alberta Division office is located in Edmonton, Alberta. The mission of the Multiple Sclerosis Society of Canada is: To be a leader in finding a cure for multiple sclerosis and enabling people affected by MS to enhance their quality of life. For more information visit www.mssociety.ca BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal Phase II/III clinical trial across Canada and Europe. Click Here For further information on BioMS: NEW DRUG IN PIPELINE: MBP8298 |